Nat. Rev. Nephrol. doi: /nrneph

Slides:

Advertisements

Similar presentations

Volume 66, Issue 5, Pages (November 2004)

Advertisements

Volume 66, Issue 5, Pages (November 2004)

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 2 Pathology of scleroderma renal crisis

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 2 Expression of complement activation products in renal samples

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Currently recognized factors that influence the development of scleroderma renal crisis Figure 1 | Currently recognized factors that influence.

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Specificity of the various epidermal growth factor (EGF)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 Localization of ErbB receptors and ligands within the nephron

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Figure 6 Hypothetical effect of starting therapy for autosomal

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Chapter 2: Use of iron to treat anemia in CKD

Nat. Rev. Nephrol. doi: /nrneph

Volume 70, Issue 11, Pages (December 2006)

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Nat. Rev. Cardiol. doi: /nrcardio

Volume 57, Issue 1, Pages (January 2000)

Copyright © 2013 Elsevier Inc. All rights reserved.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Unilateral renal cystic disease

Harold M. Aukema, Ihsan Housini Kidney International

Copyright © 2013 Elsevier Inc. All rights reserved.

Volume 57, Issue 1, Pages (January 2000)

Volume 64, Issue 4, Pages (October 2003)

Calcifications in autosomal dominant polycystic kidneys.

Nat. Rev. Nephrol. doi: /nrneph

Justin Mathew et al. Int J Spine Surg 2013;7:e29-e38

Volume 55, Issue 2, Pages (February 1999)

Volume 66, Issue 5, Pages (November 2004)

Presentation transcript:

Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.91 Figure 5 Cross sections of kidneys from a rat model of polycystic kidney disease (cy/+ Han:SPRD) Figure 5 | Cross sections of kidneys from a rat model of polycystic kidney disease (cy/+ Han:SPRD). a,c | Control animals. b,d | Animals treated with the epidermal growth factor receptor (EGFR) inhibitor EKI-785. Administration of EKI-785 reduced the severity of cystic disease as reflected by a decrease in kidney size, reduced cyst development and less fibrosis. Reproduced with permission from © 2003 International Society of Nephrology. Published by Elsevier Inc. Torres, V. E. et al. Kidney Int. 64, 1573–1579 (2003)102. Reproduced with permission from © 2003 International Society of Nephrology. Published by Elsevier Inc. Torres, V. E. et al. Kidney Int. 64, 1573–1579 (2003)102. Harskamp, L. R. et al. (2016) The epidermal growth factor receptor pathway in chronic kidney diseases Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.91